Non-Patent Exclusivity Period Proposed For Biologics In Face Of Follow-Ons
Executive Summary
A period of non-patent exclusivity for biologic products is necessary to preserve incentives for innovation in the face of follow-on biologics, attorneys argue in an article in the March/April issue of Health Affairs
You may also be interested in...
EU Biosimilar Guidance Offers Window To Bypass Comparative Trials
Manufacturers seeking regulatory approval of a follow-on biologic in the EU may be able to forgo clinical comparability trials under certain conditions, according to final guidelines on similar biologics issued by the European Medicines Agency March 8
Tale Of Two Pathways: Follow-On Biologics Move Forth In EU, Stall In U.S.
The European Medicines Agency's endorsement of Sandoz' human growth hormone Omnitrope could put further pressure on U.S. regulators to develop an approval pathway for follow-on biologics
Follow-On Biologics Could Gain From “Bolar Amendment” Ruling – Attorney
A Supreme Court ruling that extends "Bolar Amendment" protection to preclinical research on new drug candidates could aid the development of follow-on biologics, attorney Kathleen Madden Williams (Palmer & Dodge) said